[Cost-effectiveness analysis of methods for thromboprophylaxis after orthopedic surgery].
Omel'ianovskiĭ
V V
VV
Zagorodniĭ
N V
NV
Margieva
A V
AV
Tsfasman
F M
FM
D000368:Aged; D000925:Anticoagulants / Q000191:economics* / Q000627:therapeutic use; D019644:Arthroplasty, Replacement, Hip / Q000009:adverse effects*; D019645:Arthroplasty, Replacement, Knee / Q000009:adverse effects*; D001562:Benzimidazoles / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D000069604:Dabigatran; D017984:Enoxaparin / Q000191:economics* / Q000627:therapeutic use; D005260:Female; D017048:Health Care Costs; D006801:Humans; D008297:Male; D011183:Postoperative Complications / Q000517:prevention & control*; D011725:Pyridines / Q000191:economics* / Q000627:therapeutic use; D013923:Thromboembolism / Q000401:mortality / Q000517:prevention & control*; D016896:Treatment Outcome
D000925:Anticoagulants; D001562:Benzimidazoles; D017984:Enoxaparin; D011725:Pyridines; D000069604:Dabigatran